Compare Stocks: CGEM, GRFS, CRSP, and EWTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$21.08 -1.3%	$19.72	$5.68 ▼ $23.19	$1.36B	0.02	747,821 shs	3.25 million shs
CRSP CRISPR Therapeutics	$56.56 -1.3%	$53.08	$44.12 ▼ $78.48	$5.47B	1.76	1.40 million shs	3.38 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$4.92B	0.32	1.16 million shs	1.99 million shs
GRFS Grifols	$7.31 -1.2%	$7.75	$6.96 ▼ $10.23	$4.98B	0.67	370,705 shs	367,746 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-1.31%	+2.38%	-6.39%	+40.25%	+255.48%
CRSP CRISPR Therapeutics	-1.34%	+9.36%	-5.43%	+4.57%	-4.25%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%
GRFS Grifols	-1.22%	-3.18%	-11.39%	-1.22%	-25.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$21.08 -1.3%	$19.72	$5.68 ▼ $23.19	$1.36B	0.02	747,821 shs	3.25 million shs
CRSP CRISPR Therapeutics	$56.56 -1.3%	$53.08	$44.12 ▼ $78.48	$5.47B	1.76	1.40 million shs	3.38 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$4.92B	0.32	1.16 million shs	1.99 million shs
GRFS Grifols	$7.31 -1.2%	$7.75	$6.96 ▼ $10.23	$4.98B	0.67	370,705 shs	367,746 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-1.31%	+2.38%	-6.39%	+40.25%	+255.48%
CRSP CRISPR Therapeutics	-1.34%	+9.36%	-5.43%	+4.57%	-4.25%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%
GRFS Grifols	-1.22%	-3.18%	-11.39%	-1.22%	-25.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.00	56.55% Upside
CRSP CRISPR Therapeutics	2.59	Moderate Buy	$67.94	20.12% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	11.06% Upside
GRFS Grifols	1.67	Reduce	$10.00	36.80% Upside

Current Analyst Ratings Breakdown

Latest CGEM, GRFS, CRSP, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/31/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$82.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/24/2026	CGEM Cullinan Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
8/13/2026	CGEM Cullinan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$39.00 ➝ $42.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
CRSP CRISPR Therapeutics	$3.51M	1,558.06	N/A	N/A	$20.17 per share	2.80
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
GRFS Grifols	$8.51B	0.58	$1.42 per share	5.16	$12.64 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	11/5/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	38.47	5.46	0.27	5.54%	6.21%	2.39%	11/10/2026 (Estimated)

Latest CGEM, GRFS, CRSP, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.23%	N/A	47.37%	N/A

Latest CGEM, GRFS, CRSP, and EWTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	8.42	8.42
CRSP CRISPR Therapeutics	0.34	17.85	17.85
EWTX Edgewise Therapeutics	N/A	16.24	16.24
GRFS Grifols	1.10	2.37	0.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CRSP CRISPR Therapeutics	69.20%
EWTX Edgewise Therapeutics	N/A
GRFS Grifols	N/A

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	8.60%
CRSP CRISPR Therapeutics	5.20%
EWTX Edgewise Therapeutics	21.30%
GRFS Grifols	0.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable

CGEM, GRFS, CRSP, and EWTX Headlines

Recent News About These Companies

Grifols (NASDAQ:GRFS) Upgraded by Wall Street Zen to "Buy" Rating

September 19 at 1:30 AM | americanbankingnews.com

Grifols (NASDAQ:GRFS) Rating Increased to Buy at Wall Street Zen

September 19 at 1:29 AM | marketbeat.com

GRFS - Grifols, S.A.

September 17 at 2:16 PM | seekingalpha.com

Grifols: Better Plasma Economics Can Unlock A Discounted Equity

September 16 at 10:00 PM | seekingalpha.com

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

September 8, 2026 | zacks.com

Grifols (NASDAQ:GRFS) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

August 25, 2026 | marketbeat.com

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

August 10, 2026 | markets.businessinsider.com

Grifols Announces Completion of SPARTA Phase 3 Trial Follow-Up for Prolastin-C in Alpha-1 Emphysema

August 10, 2026 | quiverquant.comQ

Grifols Reshapes Board and Committee Leadership After Director Resignation

July 30, 2026 | tipranks.com

Grifols (GRFS) Q2 2026 Earnings Call Transcript

July 29, 2026 | finance.yahoo.com

Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet

July 29, 2026 | tipranks.com

Grifols, S.A. 2026 Q2 - Results - Earnings Call Presentation

July 28, 2026 | seekingalpha.com

Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings

July 28, 2026 | quiverquant.comQ

Grifols SA Q2 2026 earnings preview

July 28, 2026 | msn.com

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

July 16, 2026 | globenewswire.com

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

July 3, 2026 | seekingalpha.com

Grifols Reshapes Board and ESG Committee Following Director Resignation

June 22, 2026 | tipranks.com

Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment

June 19, 2026 | finance.yahoo.com

Grifols Shareholders Approve 2025 Accounts and July Dividend, Renew Deloitte Mandate

June 18, 2026 | tipranks.com

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

June 4, 2026 | seekingalpha.com

Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

June 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, GRFS, CRSP, and EWTX Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$21.08 -0.28 (-1.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.63 -0.45 (-2.13%)

As of 09/18/2026 07:30 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$56.56 -0.77 (-1.34%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$57.46 +0.89 (+1.58%)

As of 09/18/2026 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Edgewise Therapeutics NASDAQ:EWTX

$45.32 -1.62 (-3.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.85 -0.47 (-1.04%)

As of 09/18/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Grifols NASDAQ:GRFS

$7.31 -0.09 (-1.22%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.30 -0.01 (-0.21%)

As of 09/18/2026 04:43 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, GRFS, CRSP, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, GRFS, CRSP, and EWTX Earnings

Compare Dividends

Latest CGEM, GRFS, CRSP, and EWTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, GRFS, CRSP, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, GRFS, CRSP, and EWTX Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

CRISPR Therapeutics NASDAQ:CRSP

Edgewise Therapeutics NASDAQ:EWTX

Grifols NASDAQ:GRFS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, GRFS, CRSP, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, GRFS, CRSP, and EWTX Earnings

Compare Dividends

Latest CGEM, GRFS, CRSP, and EWTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, GRFS, CRSP, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, GRFS, CRSP, and EWTX Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

CRISPR Therapeutics NASDAQ:CRSP

Edgewise Therapeutics NASDAQ:EWTX

Grifols NASDAQ:GRFS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools